US deal for ATL1102, page-24

From the previous experience:

The FDA and the EMA go their separate ways on DMD: CHMP slaps down Sarepta but offers rival PTC an expanded market

https://endpts.com/the-fda-and-the-ema-go-their-separate-ways-on-dmd-chmp-slaps-down-sarepta-but-offers-rival-ptc-an-expanded-market/

"European and US regulators occasionally take completely conflicting stands on drugs, and nowhere is that more evident than in Duchenne muscular dystrophy."

"...there are plenty of industry execs who believe that neither drug should be on the market with the data that’s been available so far. But they don’t get a vote."

YES! I think both FDA and EMA should work hand in hand for any drugs development including DMD!!